The roles of BDNF, S100B, and oxidative stress in interferon-induced depression and the effect of antidepressant treatment in patients with chronic viral hepatitis: A prospective study

Journal of Psychosomatic Research

Volumn 76, Issue 3, 2014, Pages 227-232

  Cicek, Ismet Esra ^a   Cicek, Erdinc ^b   Kayhan, Fatih ^b   Uguz, Faruk ^c   Erayman, ibrahim ^c   Kurban, Sevil ^c   Yerlikaya, F Hümeyra ^c   Kaya, Nazmiye ^c  

^a Research and Training Hospital ^*  (Turkey)

^b MEVLANA UNIVERSITY   (Turkey)

^c NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

Author keywords

Depression; Interferon; Neurotrophic factors; Oxidative stress

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PROTEIN S100B;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; DEMOGRAPHY; DRUG INDUCED DISEASE; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDY; PROTEIN FUNCTION; PSYCHIATRIC TREATMENT; SOCIAL STATUS; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; YOUNG ADULT;

DEPRESSION; INTERFERON; NEUROTROPHIC FACTORS; OXIDATIVE STRESS;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; YOUNG ADULT;

EID: 84893719133     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2014.01.003     Document Type: Article

References (36)

1. Malek-Ahmadi P, Hilsabeck RC Neuropsychiatric complications of interferons: classification, neurochemical bases, and management. Ann Clin Psychiatry 2007, 19:113-123. [Review].
2. Raison CL, Demetrashvili M, Capuron L, Miller AH Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-123. [Review].
3. Asnis GM, De La Garza R Interferon-induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:808-818. [Review].
4. Loftis JM, Hauser P The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004, 82:175-190. [Review].
5. Wichers MC, Maes M The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004, 29:11-17.
6. Hayley S, Poulter MO, Merali Z, Anisman H The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005, 135:659-678.
7. Yuluǧ B, Ozan E, Gönül AS, Kilic E Brain-derived neurotrophic factor, stress and depression: a minireview. Brain Res Bull 2009, 78:267-269.
8. Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport 2002, 13:1675-1678.
9. Bilici M, Efe H, Köroǧlu MA, Uydu HA, Bekaroǧlu M, Deǧer O Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001, 64:43-51.
10. Herken H, Gurel A, Selek S, Armutcu F, Ozen ME, Bulut M, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007, 38:247-252.
11. Dikici I, Mehmetoglu I, Dikici N, Bitirgen M, Kurban S Investigation of oxidative stress and some antioxidants in patients with acute and chronic viral hepatitis B and the effect of interferon-alpha treatment. Clin Biochem 2005, 38:1141-1144.
12. First MB, Spitzer RL, Gibbon M, Williams JBW Structured Clinical Interview for DSM-IV Clinical Version (SCID-I/CV) 1997, American Psychiatric Press, Washington D.C.
13. Özkürkçügil A, Aydemir Ö, Yi;ldi;z M, Danaci; E, Köroǧlu E Adaptation and reliability study of Structured Clinical Interview for DSM-IV Axis I disorders. Turk J Drug Ther 1999, 12:233-236. [in Turkish].
14. Williams BW A structured interview guide for Hamilton Depression Rating Scale. Arch Gen Psychiatry 1978, 45:742-747.
15. Akdemir A, Örsel S, Daǧ I, Işcan N, Özbay H Hamilton depresyon derecelendirme ölçeǧi (HDDÖ)'nin geçerliliǧi, güvenilirliǧi ve klinikte kullani;mi;. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996, 4:251-259. [in Turkish].
16. Hamilton M The assessment of anxiety states by rating. Br J Med Psychol 1959, 32:50-55.
17. Yazi;ci; MK, Demir B, Tanri;verdi N, Karaaǧaoǧlu E, Yolaç P Hamilton Anksiyete Deǧerlendirme Ölçeǧi, deǧerlendiriciler arasi; güvenirlik ve geçerlilik çali;şmasi;. Turk Psikiyatri Derg 1998, 9:114-117. [in Turkish].
18. Erel O A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005, 38:1103-1111.
19. Erel O A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004, 37:277-285.
20. Horikawa N, Yamazaki T, Izumi N, Uchihara M Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003, 25:34-38.
21. Fontana RJ, Schwartz SM, Gebremariam A, Lok AS, Moyer CA Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 2002, 43:378-385.
22. Fontana RJ, Kronfol Z, Lindsay KL, Bieliauskas LA, Padmanabhan L, Back-Madruga C, et al. Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol 2008, 103:2766-2775.
23. Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Calès P, Garré JB Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 2003, 4:115-118.
24. Koskinas J, Merkouraki P, Manesis E, Hadziyannis S Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. Dig Dis 2002, 20:284-288.
25. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002, 7:942-947.
26. Capuron L, Ravaud A, Miller AH, Dantzer R Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004, 18:205-213.
27. Vahip S, Yazi;ci; O, Akdemir A, Bozkurt A. Duygudurum Bozukluklari;. Sadock BJ, Sadock VA (Edts). Kaplan&Sadock Klinik Psikiyatri. Aydi;n H, Bozkurt A (Çeviri editörleri). Güneş Kitabevi 2005 (in Turkish).
28. Malaguarnera M, Laurino A, Di Fazio I, Pistone G, Castorina M, Guccione N, et al. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 2001, 21:273-278.
29. Kenis G, Prickaerts J, van Os J, Koek GH, Robaeys G, Steinbusch HW, et al. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?. Int J Neuropsychopharmacol 2011, 14:247-253.
30. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 2009, 43:247-254.
31. Aydemir O, Deveci A, Taneli F The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:261-265.
32. Lim ET, Petzold A, Leary SM, Altmann DR, Keir G, Thompson EJ, et al. Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. J Negat Results Biomed 2004, 13:4.
33. Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, et al. S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 2003, 13:235-239.
34. Hetzel G, Moeller O, Evers S, Erfurth A, Ponath G, Arolt V, et al. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology (Berl) 2005, 178:161-166.
35. Nishi M, Kawata M, Azmitia EC Trophic interactions between brain-derived neurotrophic factor and s100beta on cultured serotonergic neurons. Brain Res 2000, 868:113-118.
36. Serejo F, Emerit I, Filipe PM, Fernandes AC, Costa MA, Freitas JP, et al. Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features. Can J Gastroenterol 2003, 17:644-650.